Daniel Catovsky

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Familial multiple myeloma
    Daniel Catovsky
    Institute of Cancer Research, Sutton, Surrey, UK
    Haematologica 90:3-4. 2005
  2. ncbi Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
    D Catovsky
    Section of Haemato oncology, Institute of Cancer Research, Sutton, UK
    Lancet 370:230-9. 2007
  3. ncbi Chlorambucil--still not bad: a reappraisal
    Daniel Catovsky
    Section of Haemato oncology, The Institute of Cancer Research, Sutton, United Kingdom
    Clin Lymphoma Myeloma Leuk 11:S2-6. 2011
  4. ncbi Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Haematol 150:473-9. 2010
  5. ncbi Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial
    David Gonzalez
    Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 29:2223-9. 2011
  6. ncbi Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Mol Genet 19:1840-5. 2010
  7. ncbi Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, United Kingdom
    Blood 114:4843-6. 2009
  8. ncbi The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
    Claire Dearden
    Royal Marsden National Health Service NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Blood 111:1820-6. 2008
  9. ncbi The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia
    Monica Else
    Section of Haemato oncology, Royal Marsden Hospital Institute of Cancer Research, Sutton, United Kingdom
    Cancer 110:2240-7. 2007
  10. ncbi Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
    Monica Else
    The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
    Br J Haematol 145:733-40. 2009

Detail Information

Publications102 found, 100 shown here

  1. ncbi Familial multiple myeloma
    Daniel Catovsky
    Institute of Cancer Research, Sutton, Surrey, UK
    Haematologica 90:3-4. 2005
  2. ncbi Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
    D Catovsky
    Section of Haemato oncology, Institute of Cancer Research, Sutton, UK
    Lancet 370:230-9. 2007
    ..We aimed to establish whether this treatment combination provided greater survival benefit than did chlorambucil or fludarabine...
  3. ncbi Chlorambucil--still not bad: a reappraisal
    Daniel Catovsky
    Section of Haemato oncology, The Institute of Cancer Research, Sutton, United Kingdom
    Clin Lymphoma Myeloma Leuk 11:S2-6. 2011
    ..It remains a useful drug for patients unfit to receive more intensive combinations. However, both the dose and duration of treatment are important...
  4. ncbi Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Haematol 150:473-9. 2010
    ..CLL risk increased with increasing numbers of risk alleles (P(trend) = 1.40 x 10(-15)), consistent with a polygenic model of disease susceptibility. These data validate the relationship between common variation and risk of CLL...
  5. ncbi Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial
    David Gonzalez
    Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 29:2223-9. 2011
    ..We aimed to address the frequency and prognostic value of TP53 abnormalities in patients with CLL in the context of a prospective randomized trial...
  6. ncbi Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Mol Genet 19:1840-5. 2010
    ..These four SNPs map to a 3 kb region of the 3'-UTR of IRF4, consistent with the causal basis of the association being mediated through differential IRF4 expression...
  7. ncbi Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, United Kingdom
    Blood 114:4843-6. 2009
    ..Our analysis provides no evidence that common variation in CXCR4 defined by rs228014 influences the risk of CLL, but that functional coding mutations in CXCR4 may contribute to familial CLL...
  8. ncbi The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
    Claire Dearden
    Royal Marsden National Health Service NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Blood 111:1820-6. 2008
    ..In conclusion, DAT status at the time of initiation of therapy provides a new prognostic indicator, although FC may protect against AHA. This trial was registered at http://isrctn.org as no. 58585610...
  9. ncbi The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia
    Monica Else
    Section of Haemato oncology, Royal Marsden Hospital Institute of Cancer Research, Sutton, United Kingdom
    Cancer 110:2240-7. 2007
    ..They continue to be effective at second- and even third-line therapy; however, alternative treatments are needed for patients who are or have become refractory to these agents or whose remissions are shorter with each course of therapy...
  10. ncbi Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
    Monica Else
    The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
    Br J Haematol 145:733-40. 2009
    ..Overall only eight patients died of HCL-related causes. Patients achieving a CR can expect a normal lifespan...
  11. ncbi Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence
    Monica Else
    The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, UK
    Leuk Lymphoma 52:75-8. 2011
    ..006). The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL. The results suggest an added benefit compared with single-agent purine analog therapy...
  12. ncbi A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
    Maria Chiara Di Bernardo
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 40:1204-10. 2008
    ..32 (rs11083846, PRKD2; P = 3.96 x 10(-9)). These data provide the first evidence for the existence of common, low-penetrance susceptibility to a hematological malignancy and new insights into disease causation in CLL...
  13. ncbi Lack of a relationship between the common 18q24 variant rs12953717 and risk of chronic lymphocytic leukemia
    Peter Broderick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Leuk Lymphoma 49:271-2. 2008
    ..99 (95% CI: 0.85 - 1.16) and 0.91 (95% CI: 0.74 - 1.11) for heterozygotes and TT homozygotes, respectively. These data suggests variation at SMAD7 does not significantly contribute to an inherited susceptibility to CLL...
  14. ncbi Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk
    Dalemari Crowther-Swanepoel
    Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:132-6. 2010
    ..2 (rs783540, CPEB1; OR = 1.18; P = 3.67 x 10(-6)) and 18q21.1 (rs1036935; OR = 1.22; P = 2.28 x 10(-6)). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy...
  15. ncbi T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature
    Nnenna Osuji
    Section of Haemato oncology, Institute of Cancer Research, London, United Kingdom
    Cancer 107:570-8. 2006
    ..To the authors' knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies...
  16. ncbi Inherited genetic susceptibility to monoclonal B-cell lymphocytosis
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 116:5957-60. 2010
    ..27; P = 7.75 × 10(-3)), rs2456449 (OR = 1.31; P = 3.14 × 10(-3)), and rs735665 (OR = 1.63; P = 6.86 × 10(-6)). Collectively, these data provide support for genetic variation influencing CLL risk through predisposition to MBL...
  17. ncbi Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL
    Alison Morilla
    Section of Haemato oncology, The Institute of Cancer Research, Sutton, Surrey, UK
    Leuk Lymphoma 49:2108-15. 2008
    ..Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone...
  18. ncbi Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Haematol 154:229-33. 2011
    ..These data provide further evidence for the involvement of common genetic variants in CLL risk and insight into the biological basis of disease development...
  19. ncbi Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial
    Monica Else
    Section of Haemato oncology, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Haematol 143:690-7. 2008
    ..001*). These findings support the recommendation to begin treatment when patients experience symptomatic disease, to improve HRQoL...
  20. ncbi Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 111:1625-33. 2008
    ..To facilitate the identification of prognostic markers through pooled analyses, we have made all data from our analysis publicly available...
  21. ncbi Long-term results for pentostatin and cladribine treatment of hairy cell leukemia
    Claire E Dearden
    Department of Haemato Oncology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Leuk Lymphoma 52:21-4. 2011
    ..Overall, only eight patients have died of HCL-related causes. Patients with HCL who achieve a CR can expect a normal lifespan...
  22. ncbi Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
    Claire E Dearden
    The Royal Marsden National Health Service NHS Trust, Sutton, United Kingdom
    Blood 118:5799-802. 2011
    ..Alemtuzumab delivered intravenously, but not subcutaneously, remains the treatment of choice for previously untreated T-PLL. This study is registered at www.eudract.ema.europa.eu as #2004-004636-31...
  23. ncbi Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
    Dalemari Crowther-Swanepoel
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
    Blood 111:5691-3. 2008
    ..These observations provide evidence that familial CLL is essentially indistinguishable from sporadic CLL, favoring a genetic basis to disease development in general rather than a simple environmental etiology...
  24. ncbi Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia
    Gabrielle S Sellick
    Section of Cancer Genetics, Brooks Lawley Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Leuk Res 30:1573-6. 2006
    ..None of the SNPs were individually significantly associated with risk of CLL and there was no evidence for epistatic interaction between loci. Our study does not support the postulate that variants of ARLTS1 influence the risk of CLL...
  25. ncbi Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review
    Nnenna Osuji
    Section of Haemato oncology, Royal Marsden Hospital Foundation Trust Institute of Cancer Research, London UK
    Am J Surg Pathol 29:935-41. 2005
    ....
  26. ncbi Causation of chronic lymphocytic leukemia--insights from familial disease
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Leuk Res 27:871-6. 2003
    ..Here, we review the current status of knowledge about inherited susceptibility to CLL...
  27. ncbi Differential diagnosis in chronic lymphocytic leukaemia
    Estella Matutes
    Haemato oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, 203 Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 20:367-84. 2007
    ..Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy...
  28. ncbi Diagnostic issues in chronic lymphocytic leukaemia (CLL)
    Estella Matutes
    Section of Haemato Oncology Department, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 23:3-20. 2010
    ..In atypical CLL, histology and/or molecular genetics may be required to exclude other B-cell disorders...
  29. ncbi Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia
    Rosa Ruchlemer
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Br J Haematol 118:952-8. 2002
    ..Differences seen between MCL and CLL in spleen size, and in response of the leucocytosis suggest a central role for the spleen in the evolution of MCL with leukaemia...
  30. ncbi CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease
    Mariano P Scolnik
    Inmunología Oncológica, IIHEMA, Academia Nacional de Medicina de, Buenos Aires, Argentina
    Leuk Res 26:615-9. 2002
    ..Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML...
  31. ncbi Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia
    Vasantha Brito-Babapulle
    FRC Path, Academic Department of Hematology and Cytogenetics, Royal Marsden NHS Trust Institute of Cancer Research, 203, Fulham Road, London SW3 6JJ, UK
    Haematologica 87:357-62. 2002
    ....
  32. ncbi p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome
    V Brito-Babapulle
    Department of Academic Haematology Cytogenetics, Royal Marsden Hospital NHS Trust and Institute of Cancer Research, London, UK
    Br J Haematol 110:180-7. 2000
    ..Alternatively, the frequent loss of the p53 gene could be associated with the deletion of an adjacent gene, which could be involved in the pathogenesis of these diseases...
  33. ncbi Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cells
    R Clutterbuck
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Exp Hematol 28:1120-8. 2000
    ..We have investigated the roles of interleukin-6 and other gp130-dependent ligands on the proliferation of macrophage-lineage hemopoietic progenitor cells...
  34. ncbi The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
    Leuk Lymphoma 45:2007-15. 2004
    ..Splenectomy is a useful treatment option in this group of patients...
  35. ncbi Definition of acute biphenotypic leukemia
    E Matutes
    Academic Department of Hematology and Cytogenetics, Royal Marsden Hospital, London, UK
    Haematologica 82:64-6. 1997
    ..In this work we analyze diagnostic criteria for BAL...
  36. ncbi Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia
    N Osuji
    Section of Haemato oncology, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 50:547-54. 2007
    ..To augment the limited literature on bone marrow (BM) appearances in T-cell large granular lymphocyte (LGL) leukaemia and to identify a histological signature to aid in diagnosis of this condition...
  37. ncbi Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia
    V Brito-Babapulle
    Academic Department of Haematology and Cytogenetics Institute of Cancer Research, London, UK
    Br J Haematol 114:327-32. 2001
    ..Thus, 13q14.3 deletions could contribute to the development of overt leukaemia in T-PLL, but the involvement of more than one gene in the region cannot be excluded...
  38. ncbi TCL1 is activated by chromosomal rearrangement or by hypomethylation
    M R Yuille
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton Surrey SM2 5NG, UK
    Genes Chromosomes Cancer 30:336-41. 2001
    ..We discuss the significance of this for CLL tumorigenesis and for genomewide hypomethylation in CLL...
  39. ncbi The variant form of hairy-cell leukaemia
    E Matutes
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Best Pract Res Clin Haematol 16:41-56. 2003
    ..Transformation to large cell is seen in 6% of patients. The inferior survival in HCL-variant compared with typical HCL cases may reflect the chemotherapy resistance...
  40. ncbi Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma
    E Matutes
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Haematol 115:801-6. 2001
    ..This is the first case documented by molecular methods of the transformation of the pre-existing clone...
  41. ncbi Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis
    P D Thornton
    Section of Haemato-Oncology, Institute of Cancer Research, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Leuk Res 29:389-95. 2005
    ..We suggest that the relatively high incidence of transformation in this series may be due to immunosuppression mainly related to fludarabine, although other agents and prior therapies may have also contributed...
  42. ncbi Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH
    N Parry Jones
    Section of Haemato oncology, Institute of Cancer Research and Royal Marsden NHS Trust, London and Surrey, UK
    Br J Haematol 137:117-24. 2007
    ..Deletion at 17p13 did not show prognostic impact in this series. CD38, positive in two-thirds of cases, was associated with male gender and nodal disease but not with any cytogenetic abnormality, or with survival...
  43. ncbi Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemia
    Gabrielle Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Leuk Lymphoma 49:130-3. 2008
    ..No overt pathogenic mutations were identified. These findings indicate that germline mutations in RAD51, RAD51AP1, RAD51L1, RAD51L3, RAD52 and RAD54L are unlikely to be causal of an inherited predisposition to CLL...
  44. ncbi Familial chronic lymphocytic leukemia
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Semin Oncol 33:195-201. 2006
    ..Here we review the current status of knowledge relating to inherited susceptibility to CLL and the strategies that are being employed to identify disease-causing mutations...
  45. ncbi A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Blood 110:3326-33. 2007
    ..002). None of the regions coincided with areas of common chromosomal abnormalities frequently observed in CLL. These findings provide direct evidence for Mendelian predisposition to CLL and evidence for the location of disease loci...
  46. ncbi Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon
    V J Zani
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey, UK
    Blood 87:3124-34. 1996
    ..Disruption of the amino-terminus of BCL7A defines a new mechanism in the pathogenesis of a subset of high-grade B-NHL...
  47. ncbi Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years
    Monica Else
    Section of Haemato-Oncology, Royal Marsden NHS Foundation Trust/Institute of Cancer Research (ICR, Sutton, United Kingdom
    Cancer 104:2442-8. 2005
    ..True cure in HCL remains elusive, but the addition of monoclonal antibodies may be beneficial. Our results suggest that achieving CR should remain the main goal of treatment...
  48. ncbi Familial chronic lymphocytic leukemia
    Richard S Houlston
    Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Curr Hematol Malig Rep 3:221-5. 2008
    ..This article reviews current knowledge relating to inherited susceptibility to CLL and strategies that are being used to identify disease-causing mutations...
  49. ncbi Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation
    Hannah C Rudenko
    Section of Haemato oncology, The Institute of Cancer Research ICR, Sutton, Surrey, London, UK
    Leuk Lymphoma 49:1879-86. 2008
    ..02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial...
  50. ncbi Incidence of MLL rearrangement in acute myeloid leukemia, and a CALM-AF10 fusion in M4 type acute myeloblastic leukemia
    Said M H Abdou
    Academic Department of Haematology and Cytogenetics, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Leuk Lymphoma 43:89-95. 2002
    ..Our data confirm the value of combining cytogenetic, FISH and molecular analyses to define the incidence and precise nature of MLL and 11q23 abnormalities in AML...
  51. ncbi ATM mutations are rare in familial chronic lymphocytic leukemia
    Martin R Yuille
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Blood 100:603-9. 2002
    ..Common ATM missense mutations were not overrepresented. The data support previous observations that ATM mutation is associated with B-CLL. However, ATM mutations do not account for familial clustering of the disease...
  52. ncbi Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia
    Ilaria del Giudice
    Section of Hemato-Oncology, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer 104:2124-32. 2005
    ..00001). CONCLUSIONS: The current findings suggested that both ZAP-70 and CD38 should be tested prospectively in all patients with early-stage CLL...
  53. ncbi IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)
    I Del Giudice
    Section of Haemato Oncology Institute of Cancer Research, Sutton, UK
    Leukemia 20:1231-7. 2006
    ..B-PLL appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders...
  54. ncbi Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*
    Gail Jones
    Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
    Br J Haematol 156:186-95. 2012
    ..This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment of response to therapy...
  55. ncbi Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia
    Matthew F Rudd
    Sections of Cancer Genetics and Haemato Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Blood 108:638-44. 2006
    ..68, P = .0006), CHEK2 I157T (OR = 14.83, P = .0008), BRCA2 N372H (OR = 1.45, P = .0032), and BUB1B Q349R (OR = 1.42, P = .0038). Our findings implicate variants in the ATM-BRCA2-CHEK2 DNA damage-response axis with risk of CLL...
  56. ncbi Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif
    Paul S Bradshaw
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, Surrey, UK
    Oncogene 21:483-7. 2002
    ..The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer...
  57. ncbi Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 89:36-42. 2003
    ..Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of anthracyclines should be further evaluated in large randomised studies...
  58. ncbi An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma
    I Chau
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Haematol 115:786-92. 2001
    ..It has clinically significant activity with an acceptable toxicity profile. Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high-dose chemotherapy...
  59. ncbi Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
    M Ng
    Department of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 92:1352-7. 2005
    ..Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation...
  60. ncbi Characterization of a t(10;11)(p13-14;q14-21) in the monoblastic cell line U937
    J Shipley
    Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Genes Chromosomes Cancer 13:138-42. 1995
    ..Further characterization of the genetic rearrangements in U937 may lead to the isolation of genes important in leukemogenesis and provide an in vitro system for their study...
  61. ncbi A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom
    Am J Hum Genet 77:420-9. 2005
    ..01). None of the regions coincided with areas of common chromosomal abnormalities frequently observed for CLL. These findings strengthen the argument for an inherited predisposition to CLL and related B-cell LPDs...
  62. ncbi The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia
    Gabrielle S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey
    Cancer Epidemiol Biomarkers Prev 13:1065-7. 2004
    ..80-1.31). A meta-analysis of this study and five other smaller published studies provides no evidence of relationship between this P2X7 polymorphism and risk of CLL (odds ratio = 0.99, 95% confidence interval: 0.74-1.32)...
  63. ncbi MTHFR polymorphisms and risk of chronic lymphocytic leukemia
    Matthew F Rudd
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    Cancer Epidemiol Biomarkers Prev 13:2268-70. 2004
    ..97 (95% CI, 0.79-1.18) and 0.88 (95% CI, 0.62-1.24), respectively. This data indicate that the MTHFR polymorphisms C677T and A1298C do not significantly contribute to an inherited genetic susceptibility to CLL...
  64. ncbi Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysis
    B Summersgill
    UK Co-ordinating Centre for the Study of Familial Chronic Lymphocytic Leukaemia, Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, UK
    Leukemia 16:1229-32. 2002
    ..This suggests these regions may harbour a susceptibility locus for CLL. There is also some evidence that chromosome regions 2p12-p14 and 4q11-q21 may harbour predisposition genes...
  65. ncbi EPIC: an effective low toxicity regimen for relapsing lymphoma
    T Hickish
    Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, London, UK
    Br J Cancer 68:599-604. 1993
    ..The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality...
  66. ncbi Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history
    G S Sellick
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Leuk Lymphoma 48:1320-2. 2007
    ..In conclusion, our study demonstrates that MSI does not have a prominent role in the pathogenesis of B-CLL...
  67. ncbi Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21
    T G Willis
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK
    Blood 91:1873-81. 1998
    ..These data suggest that BCL9 may be the target of translocation in some B-cell malignancies with abnormalities of 1q21 and that deregulated BCL9 expression may be important in their pathogenesis...
  68. ncbi The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes
    Ilaria del Giudice
    Academic Department of Hematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Haematologica 89:303-8. 2004
    ..However CD123 does not allow the distinction between HCL-variant and SLVL, as both are CD123 negative...
  69. ncbi High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
    Moez Dungarwalla
    Haematologica 93:475-6. 2008
    ..Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections...
  70. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
    ..This study demonstrates that HDMP alone or in combination with other agents is a useful treatment strategy in refractory CLL including patients with p53 abnormalities...
  71. ncbi Granulomatous slack skin disease--disease features and response to pentostatin
    Nnenna Osuji
    Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK
    Br J Haematol 123:297-304. 2003
    ..The patient has twice achieved a good response to pentostatin after failure of combination chemotherapy. This is the first report of the successful use of the purine analogue pentostatin in the management of GSSD...
  72. ncbi Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma
    Ian Chau
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Haematol 120:970-7. 2003
    ..9-80.5%). In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients. It has clinically significant activity with a favourable toxicity profile...
  73. ncbi Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients
    Nilima Parry-Jones
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Br J Haematol 120:759-64. 2003
    ..001 for SLVL deaths). We conclude that SLVL is mainly a disease of the elderly with a relatively benign course but, when treatment is required, splenectomy is beneficial...
  74. ncbi A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
    Jenny Orchard
    Department of Haematology, Royal Bournemouth Hospital, United Kingdom
    Blood 101:4975-81. 2003
    ..We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgVH genes may help identify patients with indolent disease...
  75. ncbi Delineation of the minimal region of loss at 13q14 in multiple myeloma
    Manal O Elnenaei
    Department of Academic Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden NHS Trust, London, United Kingdom
    Genes Chromosomes Cancer 36:99-106. 2003
    ..However, a role for RFP2 in the pathogenesis of MM cannot yet be excluded, given that alternative mechanisms such as haploinsufficiency remain possible...
  76. ncbi Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations
    Anne Tierens
    Departments of Pathology and Tumor Biology, The Norwegian Cancer Institute and Radiumhospital, University of Oslo, Oslo, Norway
    Am J Pathol 162:681-9. 2003
    ..Our results indicate that marginal zone lymphomas at different anatomical localizations may derive from a similar B-cell subset...
  77. ncbi CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia
    Patrick D Thornton
    1Academic Department of Haematology and Cytogenetics, Institute of Cancer Research and Royal Marsden NHS Trust, London, UK
    Hematol J 5:145-51. 2004
    ..We conclude that 7% may be a more useful threshold for disease progression than higher values of CD38...
  78. ncbi B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia
    Rosa Ruchlemer
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Br J Haematol 125:330-6. 2004
    ..These cases illustrate the importance of tissue diagnosis with cyclin D1 staining and fluorescence in situ hybridization analysis in B-cell leukaemia with prolymphocytic features...
  79. ncbi Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
    Apostolia M Tsimberidou
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
    Cancer 107:125-35. 2006
    ..The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone...
  80. ncbi The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases
    Yang O Huh
    Department of Hematopathology, MD Anderson Cancer Centre, The University of Texas, Houston, TX 77030, USA
    Br J Haematol 136:220-8. 2007
    ..However, these neoplasms also differ from CLL cytologically and in their immunophenotype...
  81. ncbi Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment
    Nnenna Osuji
    Section of Haemato-Oncology, Department of Histopathology, Institute of Cancer Research, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom
    Leuk Res 29:225-8. 2005
    ..We highlight the resistant nature of the LGL clone and discuss the relative merits of immunomodulatory type therapy in this disease...
  82. ncbi Molecular cytogenetic study of a mantle cell lymphoma with a complex translocation involving the CCND1 (11q13) region
    Sonia Maravelaki
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research/Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Cancer Genet Cytogenet 154:67-71. 2004
    ..This case further illustrates the value of M-FISH in combination with fusion probes in elucidating complex cytogenetic abnormalities...
  83. ncbi Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings
    Caroline L Alvares
    Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London SW3 6JJ, UK
    Leuk Lymphoma 45:769-75. 2004
    ..These cases serve to highlight the biological and cytogenetic heterogenity of DLBL and emphasize the need for complementary investigations in the characterization of this entity...
  84. ncbi Definition and diagnosis of sporadic and familial chronic lymphocytic leukemia
    Daniel Catovsky
    Academic Department of Haematology, The Institute of Cancer Research and Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK
    Hematol Oncol Clin North Am 18:783-94, vii. 2004
    ..No candidate gene has been linked to the high incidence of CLL (10%) seen in families of patients with this disease...
  85. ncbi Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas
    Lynda Song
    Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois, USA
    Cancer Res 65:4554-61. 2005
    ..Assessment of cDNA array profiles should further help us to design a working model for SMRT involvement in non-Hodgkin lymphoma transformation as a novel, nonclassical tumor suppressor...
  86. ncbi Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes
    Alicja M Gruszka-Westwood
    Academic Department of Haematology and Cytogenetics, Institute of Cancer Research/Royal Marsden NHS Trust, London, United Kingdom
    Genes Chromosomes Cancer 36:57-69. 2003
    ..The presence of a high incidence of abnormalities in the established hotspot areas and in particular the finding of biallelic deletions is indicative of the existence of genes important for the pathogenesis of SLVL in these areas...
  87. ncbi p53 and mdm2 in mantle cell lymphoma in leukemic phase
    Max Solenthaler
    Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland
    Haematologica 87:1141-50. 2002
    ..This study aimed to assess the frequency, relationship and impact of p53 abnormalities and those of its inhibitor mdm2 in blastoid and non-blastoid MCL in leukemic phase...
  88. ncbi Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
    Jacques-Louis Binet
    Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0663, USA
    Blood 107:859-61. 2006
    ..Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group...
  89. ncbi Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, University of Leeds, HMDS, West Yorkshire, Surrey, United Kingdom
    Blood 100:2289-90. 2002
    ..The detection of CLL-phenotype cells provides a surrogate marker of carrier status, potentially facilitating gene identification through mapping in families and direct analysis of isolated CLL-phenotype cells...
  90. ncbi High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia
    Donald W Milligan
    Department of Haematology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
    Br J Haematol 133:173-5. 2006
    ..4% (95% confidence interval, 2.5-24%). No analysed potential risk factor was predictive for MDS/AML development. We hypothesise that potential causative factors are fludarabine, low cell dose and transplant conditioning...
  91. ncbi Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene
    Alicja M Gruszka-Westwood
    Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, UK
    Genes Chromosomes Cancer 33:206-12. 2002
    ..This is to our knowledge the first description of amplification of the CCND1/IGH fusion gene in a human neoplasm, which may have played a role in the fulminating course of the disease in this patient...
  92. ncbi Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
    Donald W Milligan
    Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom
    Blood 105:397-404. 2005
    ..Detectable molecular disease by PCR was highly predictive of disease recurrence. It is of concern that 5 of 65 (8%) patients developed posttransplant acute myeloid leukemia/myelodysplastic syndrome...
  93. ncbi Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization
    Claus L Andersen
    Department of Hematology, Laboratory of Cancer Cytogenetics, Arhus Sygehus, Tage Hansens Gade 2, DK-8000 Arhus C, Denmark
    Cancer Genet Cytogenet 156:122-8. 2005
    ..Our data suggest that SMZL constitute a genetically heterogeneous disease where gain of 3q25 and loss of 7q31 are the most likely imbalances to be involved in the pathogenesis of the disease...
  94. ncbi Obituary. David Abraham Goitein Galton
    Barbara Bain
    Leuk Lymphoma 48:2277-8. 2007
  95. ncbi Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
    Hematol J 5:47-54. 2004
    ..DNA sequencing adds little to these methods in identifying the population at risk...
  96. ncbi Diagnostic significance of CD20 and FMC7 expression in B-cell disorders
    Julio Delgado
    Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, Institute of Cancer Research, London, England
    Am J Clin Pathol 120:754-9. 2003
    ..FMC7 is of greater diagnostic value than CD20 for distinguishing CLL from other B-cell disorders; we recommend its continued use for this purpose...
  97. ncbi The WHO classification of mature T-cell leukemias
    Daniel Catovsky
    Blood 104:2989-90; author reply 2990. 2004
  98. ncbi CHEK2*1100delC and risk of chronic lymphocytic leukemia
    Gabrielle S Sellick
    Leuk Lymphoma 47:2659-60. 2006
  99. ncbi Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A
    Manal O Elnenaei
    Academic Department of Haematology and Cytogenetics, The Institute of Cancer Research and Royal Marsden Hospital Trust, 203 Fulham Road, London SW3 6JJ, UK
    Haematologica 88:529-37. 2003
    ..The incidence of the latter two events was, however, higher than previously reported. Deletion of the TP53 gene predicted resistance to chemotherapy, highlighting its importance in this disease process...
  100. ncbi Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia
    Ilaria del Giudice
    Haematologica 90:268-70. 2005
    ..During follow-up post-treatment, seven delayed responses (54%) were observed, improving the initial overall response rate of 61% to a final response rate of 77%...
  101. ncbi Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia
    Nnenna Osuji
    Section of Haemato-Oncology, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Surrey SM2 5PT, UK
    Br J Haematol 128:645-8. 2005
    ..Pregnancy thus appears to have a beneficial effect on neutrophil count in T-cell LGL leukaemia...